2
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
NET
1
Head & Neck
1
Gastrointestinal
1
Endocrine
1
Conditions
Carcinoma, Non-Small-Cell Lung
7
Thyroid Neoplasms
3
Lung Neoplasms
3
Carcinoma, Medullary
3
Thoracic Neoplasms
2
Respiratory Tract Neoplasms
2
Respiratory Tract Diseases
2
Neoplasms, Nerve Tissue
2
Neoplasms, Germ Cell and Embryonal
2
Neoplasms by Site
2
Neoplasms by Histologic Type
2
Neoplasms
2
Lung Diseases
2
Head and Neck Neoplasms
2
Gastrointestinal Neoplasms
2
Carcinoma, Bronchogenic
2
Carcinoma
2
Adenocarcinoma
2
Thyroid Diseases
1
Thyroid Cancer, Papillary
1
Solid Tumors
1
Neuroendocrine Tumors
1
Neuroectodermal Tumors
1
Neoplasms, Glandular and Epithelial
1
Neoplasm Metastasis
1
Multiple Endocrine Neoplasia Type 2a
1
Locally Advanced Thyroid Gland Carcinoma
1
Intestinal Neoplasms
1
Intestinal Diseases
1
Gastrointestinal Diseases
1
Interventions
Irinotecan
8
Bevacizumab
8
Fluorouracil
7
Leucovorin
6
Oxaliplatin
5
Capecitabine
4
Drug Therapy
3
Cetuximab
3
5,10-methylenetetrahydrofolic acid
3
Radiotherapy
2
Levoleucovorin
2
Folfox protocol
2
Colonoscopy
2
Bisacodyl
2
Aspirin
2
Artesunate
2
trametinib
1
spartalizumab
1
repotrectinib
1
pralsetinib
1
pembrolizumab
1
nazartinib
1
napabucasin
1
lutetium Lu 177 dotatate
1
guadecitabine
1
encorafenib
1
copper dotatate CU-64
1
canakinumab
1
camrelizumab
1
apatinib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Intestinal Neoplasms
×
pralsetinib
×
Clear all
NCT03037385
2025-05-31
ARROW
Hoffmann-La Roche
Phase 1/2
Completed
590 enrolled
58 charts
3 FDA